Table 1.
Comparison of demographics and clinical data between the OA-like RA and conventional RA groups.
| Variables | OA-like RA (n = 96) | Conventional RA (n = 144) | p value |
|---|---|---|---|
| Age, years | 66.9 ± 9.8 | 66.4 ± 9.1 | 0.74 |
| Male/female | 11/133 | 12/84 | 0.26 |
| Duration of disease, years | 18.4 ± 13.6 | 18.6 ± 10.5 | 0.90 |
| BMI, kg/m2 | 23.8 ± 4.1 | 22.3 ± 3.6 | 0.003* |
| Dosage of PSL, mg/day | 3.3 ± 2.9 | 3.8 ± 3.0 | 0.21 |
| Dosage of MTX, mg/week | 4.2 ± 4.2 | 3.5 ± 3.9 | 0.21 |
| Use of bDMARDs, n (%) | 30 (31.2%) | 26 (18.0%) | 0.017* |
| Level of CRP, mg/dL | 0.9 ± 1.3 | 1.6 ± 1.8 | 0.007* |
| ESR, mm/h | 39.0 ± 23.1 | 49.7 ± 29.5 | 0.004* |
| Positive ACPA, n (%) | 63/82 (76.8%) | 49/68 (72.0%) | 0.5 |
| DAS28-CRP | 2.8 ± 0.8 | 2.9 ± 0.8 | 0.53 |
| Remission, n (%) | 25 (26.0%) | 17 (11.8%) | 0.36 |
| Low, n (%) | 16 (16.6%) | 10 (6.9%) | |
| Moderate, n (%) | 41 (42.7%) | 48 (42.1%) | |
| High, n (%) | 10 (10.4%) | 9 (6.2%) |
Continuous variables are presented as mean ± standard deviation. Categorical variables are presented as number (percentage). *The level of statistical significance was set at p < 0.05.
Abbreviations: BMI body mass index, PSL prednisolone, MTX methotrexate, bDMARDs biological disease modifying anti-rheumatic drugs, CRP C-reactive protein, ESR sedimentation rate, ACPA anti-cyclic citrullinated peptide antibody, DAS disease activity score.